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ABSTRACT
Objectives: The purpose of this study is to analyze the morphological change of cell nuclei and the change of proliferating 
activity of oral malignancy and epithelial dysplasia between before and after photodynamic therapy in order to predict 
recurrence.
Material and Methods: We experienced 14 cases of oral squamous cell carcinoma, one case of verrucous carcinoma and 
seven cases of epithelial dysplasia treated by photodynamic therapy (PDT). The mean nuclear area (NA) and coefficient 
of variation of the nuclear area (NACV) of 100 nuclei per slide were calculated using computer-assisted image analysis 
in hematoxylin and eosin stained biopsy specimens before and after PDT. Additionally, proliferating cell nuclear antigen 
(PCNA) immunohistochemistry was carried out in each specimen.
Results: The mean NA after PDT was significantly lower than that before PDT in the nonrecurrent group. However, there 
was no significant difference in mean NA before and after PDT in the recurrent group. There were no significance differences 
in NACV before and after PDT in either the nonrecurrent or recurrent group. Furthermore, the PCNA labelling indices of the 
specimens after PDT was significantly lower than that before PDT in both the nonrecurrent and the recurrent group.
Conclusions: Mean nuclear area in the biopsy specimen after photodynamic therapy is likely to be a predictive marker for 
the recurrence of oral squamous cell carcinoma or epithelial dysplasia subjected to photodynamic therapy, while coefficient of 
variation of the nuclear area and proliferating cell nuclear antigen labelling indices are less helpful in predicting the recurrence 
of such lesions.
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INTRODUCTION
Photodynamic therapy (PDT) consists of the 
administration of a photosensitizer that localizes 
in malignant or premalignant lesions because of its 
relative selectivity, followed by light irradiation. 
PDT uses the localized delivery of light to activate 
the photosensitizer [1,2]. As PDT is a useful therapy 
for oral lesions because of the accessibility of light to 
the lesions, it has been applied to oral malignant and 
premalignant lesions [3-6]. However, the recurrence 
of tumours after PDT despite a good initial response 
remains problematic [7-9]. In a previous study, we 
pointed out the heterogeneous susceptibility of mouse 
tumours to PDT anti-tumour effects [10]. Furthermore, 
we also found that the nuclear area (NA) and coefficient 
of variation of the nuclear area (NACV) as well as 
proliferating cell nuclear antigen (PCNA) of tumour 
cells are useful indicators in assessing the effect on 
tumour of PDT [11,12].
We present here 14 cases of oral squamous cell carcinoma 
(SCC), one case of verrucous carcinoma and 7 cases 
of oral epithelial dysplasia (ED), which were clinically 
diagnosed as leukoplakia, treated by PDT. No biopsy, 
taken from 4 to 9 weeks after PDT, produced evidence of 
residual tumour. However, 5 cases of SCC and one case 
of ED recurred 4 to 30 months after PDT. The biopsy 
specimens before and after PDT were investigated 
using morphological analyses of the tumour and ED cell 
nuclei as well as PCNA immunohistochemistry in order 
to clarify the correlation between the histopathological 
changes of lesions after PDT and during recurrence.
MATERIAL AND METHODS
Patients and PDT
Twenty patients were diagnosed with 22 lesions having 
one or more histologically proven SCC, verrucous 
carcinoma or ED of the oral cavity (Table 1). All lesions 
were diagnosed as stage I or II (T1 or T2 N0M0) SCC, 
verrucous carcinoma or ED, and no deep extension 
to  underlying  muscle  or  bone  was  identified  by  the 
clinical,  histological  or  radiological  findings.  None 
of the patients had received prior treatment. Informed 
consent and ethical committee of Nagasaki University 
approval was obtained in each case.
Photofrin® (Axcan Pharma, Birmingham, AL, USA) 
at a dose of 2 mg/kg [3,5] was given by intravenous 
infusion 48 hours prior to surface laser irradiation. An 
excimer dye laser was used to deliver monochromatic 
red light at 630 nm. An optical fiber was applied to 
irradiate the targeted oral lesions. A light dose of 
100 - 200 J/cm2 was delivered to each area. The patients 
were counselled to avoid direct sunlight for six weeks 
following sensitization. Treated areas were biopsied 
to confirm the effects of PDT 2 to 9 weeks after laser 
irradiation.
A complete response was defined as the disappearance 
of all known disease at least 4 weeks after PDT.
Computer-assisted image analysis of cell nuclei
The cell nuclei of lesions were examined with 
computer-assisted image analysis (Macintosh Image 
1.62 on a Power Book G4, Apple Computer, Cupertino, 
CA, USA) for quantitative measurement of the nuclear 
areas. Three fields of randomly sampled hematoxylin 
and eosin stained biopsy specimens were photographed 
using a Coolpix 4500 digital camera (Nikon, Tokyo, 
Japan) at 65x magnification. After saving the captured 
image in a personal computer, 100 nuclei per slide were 
measured and the nuclear area was calculated (Figure 1). 
The mean nuclear area (NA) and standard deviation 
(SD) of NA were calculated. The NA and SD of each 
specimen were aggregated. The coefficient of variation 
of the nuclear area (NACV) was calculated as the 
objective parameter of anisonucleosis by the following 
formula: NACV (%) = (SD of NA)/(mean NA) x 100 
[13].
Figure 1. Computer-assisted image analysis of lesion cell nuclei 
(hematoxylin and eosin stain, original magnification x65).http://www.ejomr.org/JOMR/archives/2010/3/e5/e5ht.htm    J Oral Maxillofac Res 2010 (Jul-Sep) | vol. 1 | No 3 | e5 | p.3
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PCNA immunohistochemistry
Four µm sections were prepared for each specimen, 
mounted on poly L-lysine-coated glass slides, and dried 
overnight on a hot plate at 37 ˚C to promote adhesion. 
Endogenous peroxidase was inhibited by treatment with 
0.3% H2O2 in methanol for 30 min. After three washes 
in phosphate-buffered saline (PBS), the sections were 
incubated with diluted normal blocking serum for 30 
min. Anti-PCNA monoclonal mouse antibody (PC10, 
1 : 100 diluted, DAKO M0897, Denmark) was applied 
for 30 min at room temperature, followed by diluted 
biotinylated secondary antibody for 30 min, and ABC 
reagent for 30 min using a Vectastain Elite ABC Kit 
(Vector Laboratories, Burlingame, CA, USA). PBS 
was used instead of anti-PCNA antibody as a negative 
control.
The PCNA labelling index (LI) of the lesion cells was 
determined. Both the labelled and unlabelled lesion 
cells were counted with the aid of a squared eyepiece 
graticule  (Nikon,  Tokyo,  Japan)  in  square  fields 
(0.0625 mm2) at a magnification of 400x. The PCNA 
LI of the lesion cells was defined as the percentage of 
PCNA-positive cells in 1000 lesion cells counted from 
four randomly selected fields.
Statistical analysis
Statistical analysis was performed using the Mann-
Whitney U-test for the NA of biopsy specimens 
between before and after PDT in each case. Paired t-test 
was also used for statistical comparison of the mean NA 
and NACV in biopsy specimens before and after PDT in 
both the nonrecurrent and recurrent group. Differences 
between values before and after PDT were considered 
statistically  significant  if  P  values  were  less  than  or 
equal to 0.05.
RESULTS
A complete response was achieved in all cases (Figures 
2 and 3). Stomatitis was observed for one or two weeks 
after PDT in all cases. However, other severe adverse 
side effects were not observed in all cases. Furthermore, 
no evidence of residual tumour was found in biopsy 
specimen 4 to 9 weeks after PDT in cases 1 to 13. Case 
1, 2, 3-i, 4, 5 and case 17 developed recurrent lesions 
at the treatment site 4 to 30 months after PDT. These 
were treated with surgical excision or repeat PDT. The 
histological diagnosis of each case is shown in Table 1.
The mean NAs before PDT were from 54.1 to 158.8 
μm2 (median = 91.4 μm2, SD = 23.0 μm2), and those 
after PDT were from 24.6 to 106.8 μm2 (median = 66.5 
μm2, SD = 21.7 μm2). Furthermore, medians of mean 
NAs before PDT were 92.4 μm2 (SD = 23.5 μm2) and 
88.5 μm2 (SD = 23.2 μm2) in nonrecurrent group and 
recurrent group, respectively. In cases 1 and 3-i, the 
mean  NAs  after  PDT  were  significantly  larger  than 
those before PDT. In cases 2, 3-ii, 3-iii, 7 and 19, there 
was no significant difference in mean NA before and 
after PDT. In cases 4, 5, 6, 8-18 and 20, the mean NAs 
after PDT were significantly smaller than those before 
PDT (Table 1). In the nonrecurrent group, the mean 
NA after PDT was significantly lower than that before 
PDT (Figure 4A; P = 0.026), although there was no 
significant difference in mean NA before and after PDT 
in the recurrent group (Figure 4B; P = 0.5938).
The mean NACV before PDT was 36.4% (from 
15.8 to 58.1%, SD = 9.6%), and that after PDT 
was 31.3% (from 19.5 to 54.3%, SD = 9.7%) in the 
nonrecurrent group (Figure 5A), while that before 
PDT was 32.0% (from 19.9 to 38.6%, SD = 7.0%) 
and that after PDT was 28.6% (from 22.8 to 34.8%, 
SD = 4.2%) in the recurrent group (Figure 5B). 
Figure 2. Case 16 before PDT. Figure 3. Case 16, 6 weeks after PDT. Tattoos show margin of 
tumour.http://www.ejomr.org/JOMR/archives/2010/3/e5/e5ht.htm    J Oral Maxillofac Res 2010 (Jul-Sep) | vol. 1 | No 3 | e5 | p.4
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Table 1. Nuclear changes of oral lesions epithelial cells before and after photodynamic therapy
Case
(Age, Sex)
Site of lesions
(TNM classification)
Histological diagnosis
(pre-PDT/post-PDT)
Mean of NA
(μm2; pre-PDT/
post-PDT)
NACV
(%; pre-PDT/
post-PDT)
PCNA LI
(%; pre-PDT/
post-PDT)
Follow-
up or 
recurrent 
term
R
e
c
u
r
r
e
n
c
e
1 (56, F) tongue (T2N0M0) SCC/ED, moderate 57.7/82.2a 28.4/27.0 20.5/20.0 30 months +
2 (90, F) buccal mucosa (T2N0M0) SCC/ED, moderate 105.2/106.8 19.9/27.4 17.2/16.7 15 months +
3 (69, F)
i) lt. buccal mucosa (T1N0M0)
ii) rt. lower gingiva (T1N0M0)
iii) rt. buccal mucosa (T1N0M0)
SCC/ED, severe
SCC/gingivitis
SCC/ED
60.4/97.0a
93.7/96.5
90.2/85.4
32.5/22.8
36.2/54.3
44.6/26.6
36.3/20.7
27.3/25.1
22.7/7.7
11 months
37 months
37 months
+
-
-
4 (83, M) hard palate (T2N0M0) SCC/stomatitis 108.8/84.3a 38.6/27.4 44.0/21.1 15 months +
5 (70, M) oral floor (T2N0M0) SCC/stomatitis 95.2/65.8a 37.3/32.1 22.5/10.8 4 months +
6 (63, F) tongue (T2N0M0) SCC/ED, moderate 87.8/40.2a 32.1/36.7 19.8/16.6 44 months -
7 (80, F) hard palate (T1N0M0) SCC/stomatitis with moderate ED 66.0/64.6 43.7/19.5 41.9/18.8 24 months -
8 (85, F) upper gingival (T2N0M0) SCC/gingivitis 95.6/63.1a 34.2/25.8 52.7/17.0 22 months -
9 (75, M) buccal mucosa (T1N0M0) SCC/sialadenitis 127.2/24.6a 43.9/43.6 16.0/21.0 20 months -
10 (74, F) lower gingival (T1N0M0) SCC/gingivitis 82.3/53.8a 32.1/29.9 12.5/3.8 15 months -
11 (78, F) lower gingival (T1N0M0) SCC/gingivitis 97.8/59.7 a 58.1/40.4 19.6/11.9 18 months -
12 (76, M) Tongue (T2N0M0) SCC/glossitis 96.0/81.1b 39.7/27.5 25.0/5.3 18 months -
13 (66, M) lower gingival (T3N0M0) verrucous carcinoma/ED, severe 158.8/35.0a 41.6/35.3 26.7/16.4 10 months -
14 (72, M) tongue ED, moderate/ED, mild 54.1/41.6a 35.9/32.0 49.9/41.7 19 months -
15 (29, F) tongue ED, mild/glossitis 87.1/71.2a 27.2/39.3 17.1/22.0 19 months -
16 (79, F) hard palate ED, mild /ED, mild 81.9/51.7a 15.8/21.0 25.3/17.9 30 months -
17 (65, F) tongue ED, severe/glossitis 103.5/43.7a 35.6/34.8 19.1/13.7 30 months +
18 (61, M) soft palate ED/stomatitis with mild ED 82.6/59.7a 39.6/23.9 43.5/37.5 33 months -
19 (70, F) buccal mucosa ED, moderate/ED, mild 82.2/80.2 26.2/22.2 35.4/37.1 16 months -
20 (67, M) tongue ED, mild/glossitis 95.6/74.0a 31.7/22.5 35.0/47.0 7 months -
aExistence of statistically significant differences, P < 0.0001.
bExistence of statistically significant differences, P < 0.0243.
 F = female; M = male; SCC = squamous cell carcinoma; ED = epithelial dysplasia; NA = nuclear area; NACV = coefficient of variation of 
the nuclear area; PCNA LI = proliferating cell nuclear antigen labelling index; PDT = photodynamic therapy.
Figure 4A. Mean nuclear area (NA) in nonrecurrent group. There 
was  significant  difference  in  mean  NA  before  and  after  PDT 
(P = 0.0026).
Figure 4B. Mean nuclear area (NA) in recurrent group. There 
was no significant difference in mean NA before and after PDT 
(P = 0.5983).http://www.ejomr.org/JOMR/archives/2010/3/e5/e5ht.htm    J Oral Maxillofac Res 2010 (Jul-Sep) | vol. 1 | No 3 | e5 | p.5
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Figure 5A. Mean  coefficient  of  variation  of  the  nuclear  area 
(NACV) in nonrecurrent group. There was no significant difference 
in mean NACV before and after PDT (P = 0.0920).
Figure 5B. Mean  coefficient  of  variation  of  the  nuclear  area 
(NACV) in recurrent group. There was no significant difference in 
mean NACV before and after PDT (P = 0.2689).
Figure 6A. Mean proliferating cell nuclear antigen (PCNA) 
labeling indices (LIs) in nonrecurrent group. There was a significant 
difference in mean PCNA LIs before and after PDT (P = 0.0188).
Figure 6B. Mean proliferating cell nuclear antigen (PCNA) labeling 
indices (LIs) in recurrent group. There was a significant difference 
in mean PCNA LIs before and after PDT (P = 0.0496).
The mean NACV after PDT  tended to be lower than 
that before PDT in the nonrecurrent group, although the 
difference was not significant (P = 0.0920).
PCNA-positive cells were distinguished as the brown-
stained nuclei in immunohistochemical staining. The 
mean PCNA LI before PDT was 30.3% (from 12.5 to 
52.7%, SD = 12.3%), and that after PDT was 22.5% 
(from 3.8 to 47.0%, SD = 13.0%) in the nonrecurrent 
group (Figure 6A), while that before PDT was 24.3% 
(from 17.2 to 44.0%, SD = 10.9%) and that after PDT 
was 15.0% (from 10.8 to 21.1%, SD = 4.2%) in the 
recurrent  group  (Figure  6B).  There  were  significant 
differences in PCNA LI values before and after PDT 
in the both the nonrecurrent and the recurrent group 
(P = 0.0188 in nonrecurrent group, P = 0.0496 in 
recurrent group).
DISCUSSION
Morphological change in the nuclei is a useful marker 
for assessing the effects of radiotherapy [14] and 
chemotherapy [15,16].  With  regard  to  specific  PDT 
effects, plasma membranes are the most important 
targets [17,18], and mitochondria are also critical 
targets [19,20]. In our previous study, we also clarified http://www.ejomr.org/JOMR/archives/2010/3/e5/e5ht.htm    J Oral Maxillofac Res 2010 (Jul-Sep) | vol. 1 | No 3 | e5 | p.6
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that the morphological change of mouse tumour cell 
nuclei subjected to PDT was available to assess the 
anti-tumour effects of PDT [11]. In the present human 
study, the mean NA after PDT significantly decreased 
compared to that before PDT in the nonrecurrent group 
while this difference was not significant in the recurrent 
group. PDT induces DNA fragmentation in some cell 
lines [21], and may induce the reduction of cell nuclei 
after PDT. Accordingly, it was speculated that when 
PDT targets cells whose nuclei are barely susceptible 
to PDT, there is a risk of recurrence. NACV is also 
useful for objectively evaluating nuclear pleomorphism 
[13,22]. The significant reductions of NACV reflect the 
morphologic alterations of tumour nuclei with narrow 
dispersion of their size, and the value increases with 
the malignant potential of the lesion [13]. In a previous 
study, we experimentally demonstrated that the reduction 
of NACV reflects the anti-tumour effects of PDT to 
some extent [11]. However, in this study there was no 
significant difference in mean NACV before and after 
PDT in either group, although NACV after PDT was 
lower than that before PDT in the nonrecurrent group 
(P = 0.0920). On the other hand, the mean PCNA LI 
after PDT was significantly lower than that before PDT 
in the both the nonrecurrent and recurrent group. PCNA 
synthesis occurs in the latter part of G1 and throughout 
the S-phase, predominantly increasing in the S-phase 
[23], while the photosensitivity of cells increases during 
the G1 to mid-S-phase [1]. Accordingly, the significant 
decrease of PCNA LI after PDT may have resulted 
from susceptibility to PDT in the PCNA-positive 
tumour cells. These results are likely to be indicative 
that NACV and PCNA LI are not predictive markers for 
tumour recurrence after PDT.
The primary advantage of PDT is that minimal damage 
is caused to healthy tissue, and PDT can be applied 
repeatedly at the same site because the laser used in 
PDT is nonthermal. However, targets are generally 
superficial or early-stage lesions [24]. In order to apply 
PDT to advanced lesions, or to have a better prognosis, 
fractionated laser irradiation [25,26] and adjuvant 
chemotherapies [26,27] should be made available. 
Furthermore, secondary PDT is likely to be indicated 
in cases which have no significantly reduced mean NA 
in the biopsy specimen after PDT, even if there is no 
evidence of residual tumour.
CONCLUSIONS
The non-reduction of nuclear area after photodynamic 
therapy may predict a possibility of recurrence of oral 
malignancy and epithelial dysplasia, although further 
investigations on more examples will be required to 
precisely predict the recurrence of oral malignancy and 
epithelial dysplasia.
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